[ { "@graph" : [ { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#pubinfo" } ] } ], "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#Head" }, { "@graph" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_1558", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#association", "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_1558" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "https://identifiers.org/drugbank:DB00722" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "\"PRINIVIL is contraindicated in patients with: a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor hereditary or idiopathic angioedema. Do not coadminister aliskiren with PRINIVIL in patients with diabetes [see Drug Interactions (7.4) PRINIVIL is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer PRINIVIL within 36 hours of switching to or from sacubitril/valsartan, a product containing a neprilysin inhibitor [see Warnings and Precautions (5.2) Drug Interactions (7.8) Angioedema or a history of hereditary or idiopathic angioedema ( 4 Hypersensitivity ( 4 Coadministration of aliskiren with PRINIVIL in patients with diabetes ( 4 7.4 PRINIVIL is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer PRINIVIL within 36 hours of switching to or from sacubitril/valsartan, a product containing a neprilysin inhibitor ( 4\"" } ], "https://w3id.org/biolink/vocab/provided_by" : [ { "@id" : "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "https://schema.org/MedicalContraindication" } ] }, { "@id" : "https://identifiers.org/drugbank:DB00722", "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] } ], "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ] } ], "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk", "http://purl.org/dc/terms/created" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2021-08-23T12:15:44.690+02:00" } ], "http://purl.org/dc/terms/creator" : [ { "@id" : "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ { "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ { "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] }, { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "TGKotDMizhLpKLj1hlHyxQ8SVIw8wUoeTur0vtFLNSzbYvfk4aAZd6ydLbBDdO1sHcomTJFZP6sOt6AwZa6ticlDtFyVOHm5dI5T3J7cRKAhseshr9SbfsAnuRwAqwrbYfY0Y89YIOaqD029hYsjlJ1XTguhBzKR4vZF002DojQ=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk" } ] } ], "@id" : "http://purl.org/np/RAu_OKDKznq7yYDh8llqf_HaqnSJourrbv4kRtL_HUfVk#pubinfo" } ]